Qinghua Wang, Innogen CEO
December 23, 2021 09:57 AM ESTUpdated January 6, 10:06 AM
Financing

Inno­gen nets $120M to ad­vance Trulic­i­ty, Ozem­pic ri­val; ven­ture in­to man­u­fac­tur­ing

Paul Schloesser

Associate Editor

A low pro­file, Chi­nese biotech has been work­ing on de­vel­op­ing drugs for di­a­betes and meta­bol­ic dis­or­ders. Now, the com­pa­ny, known as Inno­gen Phar­ma­ceu­ti­cal Tech­nol­o­gy, has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Mer­ck buys in­to PD-1/VEGF space as Sum­mit comes for Keytru­da

Ex­clu­sive: As­cid­i­an CEO Michael Ehlers leaves Ap­ple Tree Part­ners for MPM BioIm­pact

FDA ap­proves PTC’s ul­tra-rare dis­ease gene ther­a­py for broad­er pa­tient pop­u­la­tion than Eu­rope

Met­sera rais­es $215M for stud­ies of GLP-1 and amylin obe­si­ty drugs

GSK makes case for Blenrep's re­turn with new blood can­cer sur­vival da­ta

sponsored

What Will It Take to Re­verse Fi­bro­sis in Pa­tients with Ad­vanced MASH?

A service from the Financial Times